Transfusional Iron Overload Clinical Trial
Official title:
A 4-year Extension to a Phase II a Multicenter Study Evaluating Long-term Safety, Tolerability, Pharmacokinetics and Effects on Liver Iron Concentration of Repeated Doses of 10 mg/kg/Day of Deferasirox in Pediatric Patients With Transfusion Dependent β-thalassemia Major.
In this 4-year extension study the safety, efficacy and and pharmacokinetics of deferasirox in regularly transfused pediatric patients with β-thalassemia major was assessed. Patients who successfully completed the main 1 year trial (NCT00390858) were eligible to continue in this extension trial and receive chelation therapy with deferasirox for up to 4 years.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00560820 -
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
|
Phase 1 | |
Completed |
NCT01039636 -
Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload
|
Phase 1 | |
Completed |
NCT00673608 -
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
|
Phase 4 | |
Completed |
NCT00600938 -
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
|
Phase 2 | |
Withdrawn |
NCT01927913 -
Treatment of Iron Overload Requiring Chelation Therapy
|
Phase 2 | |
Completed |
NCT01241357 -
High-Tc Susceptometer to Monitor Transfusional Iron Overload
|
Phase 2 | |
Completed |
NCT01838291 -
Active Drug Surveillance Program of Ferriprox Use
|
N/A | |
Completed |
NCT01044186 -
A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity
|
Phase 2 | |
Completed |
NCT00379483 -
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
|
Phase 2 | |
Terminated |
NCT01326845 -
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
|
Phase 4 | |
Completed |
NCT01186419 -
Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
|
Phase 2 | |
Terminated |
NCT01363908 -
Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
|
Phase 2 |